Safety data from 546 men with erectile dysfunction (ED) enrolled in three double-blind, placebocontrolled studies conducted in distinct regions of Latin America were pooled and analyzed. The most commonly reported adverse events of all causalities associated with sildenafil treatment were headache (19%), flushing (14%), dyspepsia (6%), and nasal congestion (4%), reflecting the inhibitory effects of sildenafil on cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) in the peripheral vasculature, gastroesophageal sphincter, and nasal mucosa. Visual symptoms were reported in 5.5%, reflecting sildenafil's minor inhibitory effects on cGMPspecific PDE6 in the retina. These adverse events were generally transient and mild, and rarely resulted in discontinuation of sildenafil therapy. Thus, in this representative sample of Latin American men with ED, including those with concomitant stable cardiovascular disease, sildenafil treatment was well tolerated with an incident rate of adverse events similar to reports from other patient populations.
Introduction
During the 3 years that sildenafil citrate (Viagra 1 ) has been available for clinical use, it has become the most widely used treatment for erectile dysfunction (ED) of broad-spectrum etiology. Results of shortterm, double-blind, placebo-controlled clinical trials conducted in the USA, the UK, Europe, Africa, southeast Asia, Taiwan, China, and Latin America indicate that across ethnically and culturally diverse male populations with ED, sildenafil is equally effective in improving erectile function. 1 Consistency among various patient populations can also be expected with respect to the safety profile of sildenafil, as its safety relates primarily to the development of symptoms secondary to its predominant inhibitory effects on cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) in the systemic vasculature, 2 and its weaker inhibitory effects on phosphodiesterase type 6 (PDE6) in retinal rod and cone cells. 3 Indeed, the most common adverse events (AEs) associated with sildenafil in clinical trials conducted in the USA, the UK, and Europe were headache, flushing, dyspepsia, and nasal congestion, consistent with PDE5 inhibition in the systemic vasculature, the gastroesophageal sphincter, and the nasal mucosa; and transient visual symptoms, consistent with PDE6 inhibition in the retina. 4 The results of three double-blind, randomized, placebo-controlled, multicenter clinical evaluations of sildenafil in men with ED of various etiologies that were conducted in Brazil=Mexico, 5 and in the northern (Colombia, Ecuador, and Venezuela) 6 and southern regions of South America (Argentina, Peru, Chile, and Uruguay) 7 have been reported. The results of an analysis of the pooled safety data from these three studies are reported in this paper. The results showed a safety profile among this select Latin American patient population consistent with safety profiles generated in other studies of male populations with ED in the USA and Europe.
Methods
In these three studies, patients were randomized to treatment with flexible doses of sildenafil (25 mg, 50 mg, or 100 mg) or placebo for a duration of 12 weeks. Safety was assessed by monitoring AEs that occurred during treatment with study medication or within 7 days of the end of treatment. The severity level (mild, moderate, or severe) of each AE and whether it was related to study treatment were determined by the investigator. Patients who received at least one dose of either sildenafil (n ¼ 272) or placebo (n ¼ 274) during these studies were included in the combined analysis. No formal statistical analyses were performed because of the qualitative nature of the data.
Results

Patient population
The demographic (Table 1) and clinical ( Table 2) baseline characteristics of the patients evaluated for safety were similar in the sildenafil and placebo treatment groups. In both groups, over one-half of the patients were between the ages of 45 and 64 y, the majority were Hispanic; about one-fifth were current smokers.
On average, the study participants had ED of broad-spectrum etiology (except ED due to spinal cord injury) for approximately 3 y prior to study entry. None of the participants had poorly controlled diabetes mellitus, untreated proliferative diabetic retinopathy, retinitis pigmentosa, uncontrolled major psychiatric disorder (including depression) or a significant recent (within the past 6 months) history of cardiovascular disease, including cardiac failure, myocardial infarction, stroke, unstable angina, or life-threatening arrhythmia, or blood pressure <90=50 mm Hg or >170=100 mm Hg. None of the study participants were receiving treatment with nitrates or nitric oxide donors.
Concomitant medical conditions and medications
Over one-half of the total patients had at least one concomitant disease or syndrome (327 of 546 patients; 59%); consequently, a comparable proportion of patients (314 of 546 patients; 57%) were receiving concomitant medications during the study ( Table 2 ). The most common concomitant illnesses were hypertension and diabetes mellitus, with the most common concomitant medications being antihypertensive drugs and antidiabetic drugs. This observation is consistent with the identification of hypertension and diabetes and associated drug treatments as significant correlates of ED in the epidemiological studies conducted in Brazil 8 and the northern countries of South America (Colombia, Ecuador, Venezuela), 6 as well as in other epidemiological studies. 9 Consistent with the identification of vascular disease as a risk factor for ED, 10 approximately 7% of all patients had underlying ischemic heart disease.
Approximately 13% (n ¼ 36) of the patients in the sildenafil group and 13% (n ¼ 35) of patients in the placebo group had a past or present history of benign or malignant prostate disease, and approximately 16% (n ¼ 43) and 12% (n ¼ 34) of patients in these respective groups had undergone transurethral or radical prostatectomy. This history is consistent with the finding of disorders of the prostate as well as prostatic surgery as risk factors for ED among the sample populations from Brazil 8 and Colombia= Ecuador=Venezuela. 6 A past or present history of depression (current depression is shown in Table 2 ), a common comorbid condition and risk factor among middle-aged and elderly men with ED, 9 was documented in eight patients in the sildenafil group (2.9%) and seven in the placebo group (2.6%), with 17 (3%) of the total study patients taking antidepressant drugs concomitantly.
Across these three studies, at endpoint, the majority of the patients in the sildenafil group (> 90%) were taking either 50-mg (n ¼ 32, 43%) or 100-mg doses (n ¼ 39, 53%); only three (4%) patients were taking 25-mg doses of sildenafil.
Discontinuations from the study Four (1.5%) patients receiving sildenafil and four (1.5%) patients receiving placebo discontinued treatment because of AEs of all causalities. AEs assessed by the investigator as being related to study drug resulted in discontinuation of sildenafil treatment in two (0.7%) patients and discontinuation of placebo in one (0.4%) patient. Lack of efficacy resulted in treatment discontinuation in three (1.1%) patients in the sildenafil group and four (1.5%) patients in the placebo group. Twenty-nine (11%) patients in the sildenafil group and 28 (10%) in the placebo group discontinued the study for reasons unrelated to study medication. The two AEs considered treatment related that led to discontinuation of sildenafil treatment were severe syncope (25-mg dose) that subsequently resolved with treatment, and a severe headache (100-mg dose) that resolved spontaneously. One patient who received placebo discontinued the study due to mild, transient flushing. The majority (>70%) of these AEs (all causality and treatment-related) were rated by the investigator as being mild in severity; none of these events were considered severe. c Abnormal vision: mild and transient events that included altered vision, blue tinge to vision, increased brightness of light, increased sensitivity to light. d Two cases of rhinitis (all-cause and treatment-related) were considered severe; the rest were considered mild or moderate in severity. 
Adverse events
Adverse events, regardless of causality, were reported by 125 of 272 (46%) patients receiving sildenafil, of which those that occurred in 100 of the 272 patients (37%) were assessed as being treatment-related. In comparison, among the 274 patients receiving placebo, all-cause AEs occurred in 70 (26%) patients, and treatment-related AEs occurred in 29 (11%) patients. Adverse events (all causality or treatment related) reported by 2% of patients in either group are summarized in Table 3 . The most commonly reported treatment-related AEs were headache (17%), flushing (14%), and dyspepsia (4.8%). Treatmentrelated visual abnormalities (including reports of 'abnormal vision', blue tinge to vision [chromatopsia], and increased sensitivity to light [photophobia]) were also reported by 5.1% of patients treated with sildenafil. Nasal congestion and rash also occurred with low incidence (< 3%). In one patient, 'abnormal vision', described as blurred vision, was attributed to stress, rather than to sildenafil treatment. Mild dizziness of all causalities were reported by five (1.8%) patients treated with sildenafil and four (1.5%) patients treated with placebo. Cardiovascular AEs (aside from flushing) of all causalities occurred in a similar number of patients in the sildenafil (n ¼ 16; 5.9%) and placebo (n ¼ 15; 5.5%) treatment groups. There were no discontinuations due to abnormal laboratory test results.
Headache, abnormal vision, dyspepsia, nasal congestion, dizziness, and rash were reported by three patients receiving the 25-mg dose of sildenafil. One patient reported both mild, transient headache and mild, transient abnormal vision described as increased perception of brightness on Day 16 of sildenafil treatment. This patient had previously experienced mild visual disturbances at a 50-mg dose of sildenafil on Day 1 of treatment and the dose was subsequently reduced to 25 mg. Eventually, on Day 75 of the study, this patient was permanently discontinued from sildenafil (25-mg) treatment following an episode of severe syncope that was not considered serious and which resolved with treatment. A second patient reported separate episodes of mild dyspepsia, mild nasal congestion, and mild dizziness at a 25-mg dose of sildenafil. This patient had originally been started on a 100-mg dose of sildenafil, but treatment was temporarily discontinued following repeated occurrences of moderate or severe nasal congestion, and later resumed at a lower dose of 25 mg. After this dose adjustment, subsequent episodes of nasal congestion were mild and tolerated. A third patient experienced transient episodes of mild rash following treatment with sildenafil at a 25-mg dose; the rash first appeared on Day 2 of sildenafil treatment at a 50-mg dose, prompting a reduction in dose to 25 mg.
Adverse events (all causalities) were managed by dose reductions or temporary discontinuation of treatment in 18 of 272 (6.6%) patients treated with sildenafil and seven of 274 (2.6%) patients treated with placebo. The most common AEs managed in this manner were headache (sildenafil, n ¼ 11; placebo, n ¼ 2), rhinitis described as nasal congestion (sildenafil, n ¼ 3), and flushing (sildenafil, n ¼ 3). A total of three patients with visual abnormalities had reductions in sildenafil dose, including two patients who experienced visual disturbances during treatment at 50-mg and 100-mg doses, and one patient who experienced chromatopsia (blue tinge to vision) at a 100-mg dose.
Discussion
The results of this safety analysis indicate that sildenafil treatment was well tolerated by a representative population of Latin American men with ED of broad-spectrum etiology. The rate of patients in the sildenafil and placebo treatment groups discontinuing treatment because of AEs of all causes was identical (1.5%), and < 1% of patients treated with sildenafil discontinued therapy because of treatment-related AEs. In this study population, the most commonly reported AEs of all causalities associated with sildenafil were nearly identical both in type and incidence to that reported by patients treated with sildenafil during six phase II=III placebo-controlled flexible-dose studies conducted in the USA, UK, and Europe. 4 In this patient population, sildenafil treatment was associated with an overall incidence of visual AEs (visual disturbances, bright vision, blue color tinge to vision, increased sensitivity to light) of all causalities of 5.5% and a treatment-related incidence of approximately 5%. These rates are somewhat higher than the rate of 'abnormal vision' of all causes seen in the phase II=III flexible-dose placebocontrolled studies reported previously (3%), 4 and the treatment-related rate (4%) seen in a doubleblind, placebo-controlled, flexible-dose, 12-week study of sildenafil conducted in the UK. 11 However, these differences in rate may simply reflect a dose effect, as approximately 11% of men taking 100-mg daily doses of sildenafil were reported to experience abnormal vision. 4 As observed in other studies, 4 the primary manifestation of the peripheral vasodilatory effects of sildenafil was flushing, which was reported by approximately 14% of patients receiving sildenafil. Occasionally, sildenafil can induce reductions in blood pressure, which are generally modest and not associated with cardiovascular compromise. 13 The exception is in patients taking nitrates in whom a synergistic hypotensive effect can occur that could potentially be clinically significant. 13, 14 The concurrent use of nitrates and sildenafil is therefore contraindicated. 15 Although over one-third of the patients in the sildenafil group (n ¼ 97, 36%) had either stabilized hypertension or a past or present history of ischemic heart disease concurrent with ED, cardiovascular AEs of all causalities (other than flushing) occurred at comparable rates in the sildenafil (5.9%) and placebo (5.5%) treatment groups. Syncope was the only cardiovascular AE considered related to treatment that resulted in permanent discontinuation of sildenafil in one patient. The low risk of cardiovascular AEs observed in this select Latin American patient population is consistent with results of a comprehensive analysis of safety data from 82 clinical trials of sildenafil (36 double-blind, placebocontrolled, and 46 open-label extension trials) showing no difference in the incidence of myocardial infarction (MI) or death among men treated with sildenafil and the incidence among men treated with placebo, or the incidence expected in the general population. 16 The studies included in that analysis used exclusion criteria similar to those used in the current Latin American studies, that is, only patients with stable cardiovascular disease were included. None of the cases of MI or death were considered to be related to sildenafil treatment. Similarly, results of a prescription event monitoring program showed no difference in the incidence of fatal MI or ischemic heart disease among sildenafiltreated men (n ¼ 5601) compared with the general population in the UK. 17 The medical history of the Latin American study population reflects the frequent occurrence of ED among men with cardiovascular disease. 10, 11 Consequently, numerous studies have evaluated the cardiovascular safety of sildenafil in patients with stable cardiovascular disease. 12,18 -21 Overall, these studies have found no evidence of clinically significant hemodynamic compromise in association with sildenafil treatment, which includes patients with ischemic heart disease, 12, 18, 19 hypertension controlled with antihypertensive medication, 21 or chronic stable angina. 22 In one study, rates of treatment-emergent cardiovascular AEs (other than flushing) were comparable in the sildenafil and placebo treatment groups (2% and 1%, respectively). 19 With respect to incidence rates for the most common AEs (headache, flushing, dyspepsia, visual symptoms, nasal congestion), post hoc subanalyses of safety data from controlled clinical trials 15, 20, 22 found no difference in the rates of these events between sildenafil-treated patients with and those without ischemic heart disease, 22 or between sildenafil-treated patients taking and those not taking antihypertensive medications. 21 Dizziness, hypotension, and syncope also occurred at similar rates in patients taking concomitant antihypertensive medications and in patients not taking these medications. 21 Taken together, these data suggest that sildenafil treatment is generally safe for patients with stable cardiovascular disease, provided they are not taking nitrates and they have been assessed for sexual activity-related cardiac risk. Expert consensus documents developed by panels of cardiologists provide useful guidelines for prescribing sildenafil in patients with cardiovascular disease and various levels of cardiac risk. 23 -25 
Conclusions
Results of this safety analysis indicate that in a representative sample of Latin American men with ED of broad-spectrum etiology, sildenafil treatment at doses between 25 and 100 mg was well tolerated. Consistent with findings of studies in other countries, in this Latin American patient population, the most commonly reported AEs associated with sildenafil treatment were headache, flushing, dyspepsia, vision abnormalities, and nasal congestion. These events were generally transient and mild to moderate in nature, and rarely resulted in the discontinuation of sildenafil therapy. These findings support a consistent safety profile for sildenafil across diverse patient populations with ED.
